Latest Commercial Sales News

Alpha HPA Limited has kicked off major civil works for its HPA First Project Stage 2 while securing strong sales momentum in the semiconductor sector, supported by expanded Letters of Intent covering over 60% of Stage 2 capacity.

Viva Energy has reported a stronger-than-expected first half EBITDA, buoyed by operational efficiencies and refinery margins, even as convenience sales face headwinds from tobacco regulation.

Australian Strategic Materials (ASM) reports significant progress in Q2 2025, including its first commercial heavy rare earth metals sale and a transformative low-cost production pathway at its Dubbo Project.

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.

Rhythm Biosciences has obtained a $1 million non-dilutive loan backed by its FY2025 R&D Tax Incentive rebate, aiming to accelerate the commercial rollout of its ColoSTAT® test and expand its geneType™ platform.

Argosy Minerals has executed a spot sales contract for 60 tonnes of high-purity lithium carbonate from its Rincon project, marking a significant step in its lithium market engagement.

Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.

Green Critical Minerals has raised A$7 million through an institutional placement to accelerate the commercial rollout of its Very High Density graphite technology, aiming for first revenue in early 2026.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

Syrah Resources has clarified its offtake agreement with Tesla, extending the final qualification deadline for its Vidalia anode active material facility to February 2027. Both companies continue advancing towards commercial sales despite the extended timeline.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.